ORYZON receives the INNOVATIVE SME seal from the Ministry of Science and Innovation

by Oryzon Genomics

Innovation present in Oryzon's programs in the field of epigenetics acknowledged Oryzon currently has 2 compounds in Phase II clinical studies, iadademstat and vafidemstat

Read more

ORYZON announces FDA Orphan Drug Designation granted to iadademstat for treatment of Acute Myeloid Leukemia

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today an...

Read more

ORYZON to present new clinical data and corporate updates at conferences in February and March

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announce...

Read more

ORYZON to present a corporate update and to hold multiple virtual corporate activities in January-2021

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announce...

Read more

ORYZON to present further positive efficacy data from iadademstat ALICE Phase IIa trial at the 62nd Congress of the American Society of Hematology

by Oryzon Genomics

ORYZON to present further positive efficacy data from iadademstat ALICE Phase IIa trial at the 62nd Congress of the American Society of Hematology

Read more

ORYZON receives approval to start PORTICO Phase IIb trial with vafidemstat in Borderline Personality Disorder

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today...

Read more

Oryzon announces appointment of Dr. Torsten Hoffmann as Global R&D Director and retirement of Dr. Tamara Maes

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announce...

Read more

ORYZON Reports Results for Quarter Ended September 30, 2020 and Provides Corporate Update

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported ...

Read more

ORYZON holds its 4th annual Solidarity Day

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, celebrated yest...

Read more

Potential Down’s syndrome treatment may improve cognition through epigenetic activity in brain

by Centre for Genomic Regulation

Down’s syndrome is one of the most common causes of learning disabilities. Caused by the presence of all or part of a third copy of chromosome 21, it is a genetic disorder with no known cure or trea...

Read more

ORYZON presents efficacy and safety results of its CLEPSIDRA trial with iadademstat in ED-SCLC patients at ESMO-2020

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces today...

Read more

ORYZON to present at upcoming international conferences

by Oryzon Genomics

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today...

Read more
Subscribe to Directory
Write an Article

Recent News

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

Dos investigadoras del IIS La Fe y del i...

by Instituto de Investigación Sanitaria La Fe

​Las doctoras Sandra Monfort, del Instituto de Investigación Sanita...

Photos Stream